Teva Taps UCB’s Respiratory Expertise To Promote ProAir HFA In The U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal comes as Teva seeks to capture remaining market share from CFC-containing albuterol products, which must be discontinued by year-end, firm tells "The Pink Sheet" DAILY.